polcortolone tablett
polfa pabianice pharmaceutical works - triamtsinoloon - tablett - 4mg 30tk
lederlon süstesuspensioon
riemser pharma gmbh - triamtsinoloon - süstesuspensioon - 20mg 1ml 1ml 1tk; 20mg 1ml 1ml 10tk
kenalog süstesuspensioon
krka, d.d., novo mesto - triamtsinoloon - süstesuspensioon - 40mg 1ml 1ml 5tk
triamgalen salv
paul w. beyvers gmbh - triamtsinoloon - salv - 1mg 1g 50g 1tk
ftorocort salv
gedeon richter plc. - triamtsinoloon - salv - 0,1% 15g 1tk
nasacort ninasprei, suspensioon
recipharm hc limited - triamtsinoloon - ninasprei, suspensioon - 55mcg 1mõõtannus 120mõõtannus 1tk
polcortolon tablett
adamed pharma s.a. - triamtsinoloon - tablett - 4mg 20tk
polcortolon tablett
polfa pabianice pharmaceutical works - triamtsinoloon - tablett - 4mg 50tk; 4mg 20tk
oridermyl kõrvasalv
vetoquinol s.a. - permetriin+neomütsiin+nüstatiin+triamtsinoloon - kõrvasalv - 10mg+3500rÜ+100000rÜ+0,908mg 1g 30g 1tk; 10mg+3500rÜ+100000rÜ+0,908mg 1g 10g 1tk
prezista
janssen-cilag international nv - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.